Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus

NCT05262686 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Belimumab
DRUG: Interleukin-2

Sponsor

Peking University People's Hospital